DexFEM is a double-blind response-adaptive parallel-group placebo-controlled trial in women with HMB ( 108 to be randomised ) , with active treatment the potent oral synthetic glucocorticoid dexamethasone , which is relatively resistant to 11HSD2 inactivation .